Evidence map›Paper›PMID 41881263›Full record

ArticleJournal of lipid research2026

Fenofibrate plus statin and ASCVD risk by triglyceride-rich lipoprotein cholesterol in 70,000 patients.

Youngwoo Jang, Byung Jin Kim, Yong Whi Jeong, Dae Ryong Kang, Kwang Kon Koh, Børge G Nordestgaard, Seung Hwan Han

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of lipid research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Youngwoo JangDepartment of Cardiology, Gachon University Gil Medical Center, Incheon, South Korea; Gachon University, College of Medicine, Incheon, South Korea.
Byung Jin KimDivision of Cardiology, Department of Internal Medicine, Kangbuk Samsung Hospital, Seoul, South Korea.
Yong Whi JeongDepartment of Medical Informatics and Biostatistics, Graduate School, Yonsei University, Seoul, South Korea.
Dae Ryong KangDepartment of Precision Medicine, Wonju College of Medicine, Yonsei University, Wonju, South Korea.
Kwang Kon KohK-Heart Clinic & Lab, Incheon, South Korea.
Børge G NordestgaardDepartment of Clinical Biochemistry, Copenhagen University Hospital - Herlev and Gentofte, Herlev, Denmark; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. Electronic address: Boerge.Nordestgaard@regionh.dk.
Seung Hwan HanDepartment of Cardiology, Gachon University Gil Medical Center, Incheon, South Korea; Gachon University, College of Medicine, Incheon, South Korea. Electronic address: kheartist@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Fenofibrate may offer cardiovascular benefit in statin-treated individuals with elevated triglyceride-rich lipoprotein cholesterol (TRL-C), a measure reflecting cholesterol carried in triglyceride-rich lipoproteins, yet its role remains uncertain. We investigated whether fenofibrate added to statin therapy is associated with lower risk of atherosclerotic cardiovascular disease (ASCVD), particularly in individuals with high TRL-C. We analyzed 67,662 statin-treated adults without baseline ASCVD from the Korean National Health Insurance Service cohort. Participants were stratified by median TRL-C (26 mg/dl), and propensity score matching was performed for fenofibrate users and non-users within each stratum. The primary outcome was incident ASCVD, defined as a composite of coronary artery disease, ischemic stroke, and cardiovascular death. Over a mean follow-up of 87 months, fenofibrate use was associated with lower ASCVD risk in individuals with TRL-C ≥ median (adjusted hazard ratio [HR

Indexed as

AtherosclerosisCholesterolFenofibrateHydroxymethylglutaryl-CoA Reductase InhibitorsLipoproteinsTriglyceridesAgedFemaleHumansHypolipidemic AgentsMaleMiddle AgedRisk FactorsCholesterolFenofibrateHydroxymethylglutaryl-CoA Reductase InhibitorsHypolipidemic Agentslipoprotein cholesterolLipoproteinsTriglyceridescholesterollipoproteinsmyocardial infarctionstatinstriglycerides

Identifiers

PMID41881263
PMCPMC13101280

What OpenQuestion holds

Texttitle and abstract
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.